Bonitar 400mg Tablet 10s

Introduction to Bonitar 400mg Tablet 10s

Bonitar 400mg Tablet 10s is a pharmaceutical product in tablet form primarily used for the treatment of certain types of leukemia, a cancer affecting the blood and bone marrow. Bonitar 400mg Tablet 10s is specifically formulated to help manage the disease when other treatments have not been effective or are unsuitable.

Composition of Bonitar 400mg Tablet 10s

Bonitar 400mg Tablet 10s contains Bosutinib (400mg) as its active ingredient. Bosutinib is a tyrosine kinase inhibitor that targets specific proteins necessary for cancer cell growth, thereby slowing or halting the progression of the disease.

Uses of Bonitar 400mg Tablet 10s

• Treatment of certain types of leukemia.
• Used when other leukemia treatments are ineffective or unsuitable.

Side effects of Bonitar 400mg Tablet 10s

• Common side effects include diarrhea, nausea, and fatigue.
• Serious side effects may involve liver problems, requiring regular liver function tests.

Precautions of Bonitar 400mg Tablet 10s

Patients should be aware that Bonitar 400mg Tablet 10s can cause liver issues, and it is not recommended for individuals with severe liver problems or for use during pregnancy. Regular monitoring of liver function is advised.

How to Take Bonitar 400mg Tablet 10s

The usual starting dose of Bonitar 400mg Tablet 10s for adults is 400 mg once daily with food. It is important to follow your doctor's instructions regarding dosage adjustments based on your response and any side effects experienced.

Conclusion of Bonitar 400mg Tablet 10s

Bonitar 400mg Tablet 10s, containing Bosutinib, is a therapeutic option in the class of tyrosine kinase inhibitors, primarily used for treating certain types of leukemia. Manufactured by Sun Pharmaceutical Industries Limited, it is essential for patients to adhere to prescribed dosages and be aware of potential side effects and precautions. Bonitar 400mg Tablet 10s offers a targeted approach to managing leukemia, especially when other treatments are not viable.